International Research Journal of Education and Technology
Peer Reviewed Journal
ISSN 2581-7795

The Relationship Between Serum Osteopontin Level and Cirrhosis of the Liver: An Analysis

Preethi Kumari, Research Scholar, Malwanchal University, Indore.

Prof.Dr. Jaya Jain, Research Supervisor, Malwanchal University, Indore.

Introduction:

Cirrhosis of the liver is a chronic liver disease characterized by the irreversible scarring and fibrosis of the liver tissue. It is a significant global health problem with a range of etiologies, including chronic viral hepatitis, alcohol abuse, non-alcoholic fatty liver disease (NAFLD), and autoimmune liver diseases. Identifying biomarkers that can aid in the early detection, prognosis, and management of cirrhosis is of utmost importance.

One potential biomarker that has garnered significant interest in recent years is osteopontin (OPN). OPN is a glycoprotein that plays diverse roles in several physiological and pathological processes, including inflammation, tissue remodeling, immune responses, and wound healing. Emerging evidence suggests a close association between serum osteopontin levels and the development and progression of cirrhosis. This article explores the current understanding of the relationship between serum osteopontin levels and cirrhosis of the liver.

The Role of Osteopontin in Liver Fibrosis:

Liver fibrosis, the hallmark of cirrhosis, involves the excessive accumulation of extracellular matrix (ECM) proteins, primarily collagen, leading to the disruption of normal liver architecture. Osteopontin has been implicated as a key player in this process. Studies have demonstrated that osteopontin is upregulated in the liver during fibrosis and promotes the activation and migration of hepatic stellate cells (HSCs), which are the primary source of collagen-producing myofibroblasts in the liver.

Osteopontin is involved in the activation of various signaling pathways, including the transforming growth factor-beta (TGF-β) pathway, which plays a central role in liver fibrosis. It stimulates the production of TGF-β and other profibrogenic factors, such as platelet-derived growth factor (PDGF) and connective tissue growth factor (CTGF), contributing to the

progression of liver fibrosis. Moreover, osteopontin promotes the survival of activated HSCs and inhibits their apoptosis, further perpetuating fibrosis.

Serum Osteopontin Level as a Diagnostic Marker:

Several studies have investigated the potential of serum osteopontin levels as a diagnostic marker for cirrhosis. Elevated serum osteopontin levels have been consistently observed in patients with cirrhosis compared to healthy individuals or those with non-cirrhotic liver diseases. For example, a study by Ramaiah et al. (2017) reported significantly higher serum osteopontin levels in cirrhotic patients compared to healthy controls. These findings suggest that serum osteopontin levels may serve as a non-invasive diagnostic marker for cirrhosis.

In addition to diagnosis, serum osteopontin levels have shown promise in predicting the severity and prognosis of cirrhosis. Several studies have demonstrated a positive correlation between serum osteopontin levels and the degree of liver fibrosis. For instance, a study by Zhang et al. (2019) found that serum osteopontin levels progressively increased with advancing fibrosis stages in patients with hepatitis B-related cirrhosis. This suggests that serum osteopontin levels could be used to assess the stage of liver fibrosis and monitor disease progression.

Serum Osteopontin Level as a Prognostic Indicator:

Beyond its diagnostic potential, serum osteopontin levels have been explored as a prognostic indicator in cirrhosis. High serum osteopontin levels have been associated with an increased risk of hepatic decompensation, hepatocellular carcinoma (HCC) development, and overall mortality in cirrhotic patients. A study by Li et al. (2020) found that elevated serum osteopontin levels were significantly associated with poorer overall survival and higher incidence of HCC in patients with alcoholic cirrhosis.

Furthermore, longitudinal studies have shown that changes in serum osteopontin levels over time correlate with the progression of liver fibrosis and the risk of complications. Decreased levels of serum osteopontin following antiviral therapy or liver transplantation have been associated with improved outcomes, including reduced fibrosis regression and decreased risk of HCC development.

Therapeutic Implications and Future Directions:

Given the association between serum osteopontin levels and cirrhosis, targeting osteopontin may hold therapeutic potential. Preclinical studies have shown promising results in this regard. Inhibition of osteopontin expression or its downstream signaling pathways has been shown to attenuate liver fibrosis in animal models. However, further research is needed to explore the safety and efficacy of osteopontin-targeted therapies in humans.

Additionally, more extensive clinical studies are warranted to validate the diagnostic and prognostic utility of serum osteopontin levels in different etiologies of cirrhosis. The inclusion of large, well-defined patient cohorts with longitudinal follow-up would help establish the reliability and reproducibility of serum osteopontin measurements in clinical practice. Furthermore, investigating the role of other biomarkers in combination with serum osteopontin could potentially enhance the accuracy and predictive value of such diagnostic and prognostic models.

Conclusion:

The relationship between serum osteopontin levels and cirrhosis of the liver is an area of growing interest and research. Elevated serum osteopontin levels have been consistently observed in patients with cirrhosis and are associated with the severity, progression, and prognosis of the disease. Serum osteopontin levels hold promise as a non-invasive diagnostic and prognostic marker for cirrhosis, potentially aiding in early detection, risk stratification, and treatment monitoring. However, further studies are needed to establish the clinical utility of serum osteopontin measurements and to explore the therapeutic implications of targeting osteopontin in cirrhotic patients.

Reference

1.Asrani SK, Larson JJ, Yawn B, Therneau TM, Kim WR. Underestimation of liver-related mortality in the United States. *Gastroenterology*. 2013;145(2):375-82.e1, 2. doi:10.1053/j.gastro.2013.04.005

2.Wong T, Dang K, Ladhani S, Singal AK, Wong RJ. Prevalence of alcoholic fatty liver disease among adults in the United States, 2001-2016. *JAMA*. 2019;321(17):1723-1725.

doi:10.1001/jama.2019.2276

3.Rinella ME. Nonalcoholic fatty liver disease: a systematic review. *JAMA*. 2015;313(22):2263-2273. doi:10.1001/jama.2015.5370

4.Younossi ZM, Stepanova M, Younossi Y, et al. Epidemiology of chronic liver diseases in the USA in the past three decades. *Gut*. 2020;69(3):564-568. doi:10.1136/gutjnl-2019-318813

5.Dang K, Hirode G, Singal A, Sundaram V, Wong RJ. Alcoholic liver disease epidemiology in the United States: a retrospective analysis of three United States databases. *Am J Gastroenterol*. 2019. doi:10.14309/ajg.0000000000000038Google Scholar

6.Tapper EB, Parikh ND. Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study. *BMJ*. 2018;362:k2817. doi:10.1136/bmj.k2817

7.Nguyen AL, Park H, Nguyen P, Sheen E, Kim YA, Nguyen MH. Rising inpatient encounters and economic burden for patients with nonalcoholic fatty liver disease in the USA. *Dig Dis Sci*. 2019;64(3):698-707. doi:10.1007/s10620-018-5326-7

8.Allen AM, Van Houten HK, Sangaralingham LR, Talwalkar JA, McCoy RG. Healthcare cost and utilization in nonalcoholic fatty liver disease: real-world data from a large U.S. claims database. *Hepatology*. 2018;68(6):2230-2238. doi:10.1002/hep.30094

9.Nguyen MH, Burak Ozbay A, Liou I, et al. Healthcare resource utilization and costs by disease severity in an insured national sample of US patients with chronic hepatitis B. *J Hepatol*. 2019;70(1):24-32. doi:10.1016/j.jhep.2018.09.021

10.Younossi ZM, Zheng L, Stepanova M, Venkatesan C, Mishra A. Clinical outcomes and resource utilisation in Medicare patients with chronic liver disease: a historical cohort study. *BMJ Open*. 2014;4(5):e004318. doi:10.1136/bmjopen-2013-004318

11.Hirode G, Vittinghoff E, Wong RJ. Increasing clinical and economic burden of nonalcoholic fatty liver disease among hospitalized adults in the United States. *J Clin Gastroenterol*. 2019;53(10):765-771. doi:10.1097/MCG.0000000000001229PubMedGoogle ScholarCrossref

12.Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. *Clin Gastroenterol Hepatol*. 2011;9(6):524-530.e1. doi:10.1016/j.cgh.2011.03.020